Literature DB >> 21688173

Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers.

Shenying Fang1, Ralf Krahe, Linda L Bachinski, Baili Zhang, Christopher I Amos, Louise C Strong.   

Abstract

Germline mutations in the tumor suppressor gene TP53 occur in the majority of families with Li-Fraumeni syndrome, who are at an increased risk for a wide spectrum of early onset cancers. Several genetic polymorphisms in TP53 modify its effect on cancer risk. While some studies indicate that the TP53 PIN3 deletion allele (D) accelerate tumor onset in carriers with TP53 germline mutations, other studies have shown that the TP53 PIN3 insertion allele (I) confers a significantly higher risk of developing cancer than D allele. To further determine the effects of the TP53 PIN3 polymorphism on cancer development among TP53 germline mutations and to evaluate if those are differenence between male and female carriers, we studied a total of 152 germline mutation carriers with available DNA samples that can be used for genotyping. Our results indicate that the TP53 PIN3 polymorphism has a sex-specific effect on the risk of cancer in TP53 mutation carriers, conferring cancer risk in men (P = 0.0041) but not women with DI or II genotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688173      PMCID: PMC6497528          DOI: 10.1007/s00439-011-1039-0

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  14 in total

1.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

2.  Computer programs for multilocus haplotyping of general pedigrees.

Authors:  D E Weeks; E Sobel; J R O'Connell; K Lange
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

3.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 4.  Tumors associated with p53 germline mutations: a synopsis of 91 families.

Authors:  P Kleihues; B Schäuble; A zur Hausen; J Estève; H Ohgaki
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect.

Authors:  Linda L Bachinski; Bjarne Udd; Giovanni Meola; Valeria Sansone; Guillaume Bassez; Bruno Eymard; Charles A Thornton; Richard T Moxley; Peter S Harper; Mark T Rogers; Karin Jurkat-Rott; Frank Lehmann-Horn; Thomas Wieser; Josep Gamez; Carmen Navarro; Armand Bottani; Andre Kohler; Mark D Shriver; Riitta Sallinen; Maija Wessman; Shanxiang Zhang; Fred A Wright; Ralf Krahe
Journal:  Am J Hum Genet       Date:  2003-09-10       Impact factor: 11.025

6.  Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis.

Authors:  Zheng Hu; Xiang Li; Xincai Qu; Yungang He; Brian Z Ring; Enmin Song; Li Su
Journal:  Carcinogenesis       Date:  2010-01-20       Impact factor: 4.944

7.  Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Authors:  Shenying Fang; Ralf Krahe; Guillermina Lozano; Younghun Han; Wei Chen; Sean M Post; Baili Zhang; Charmaine D Wilson; Linda L Bachinski; Louise C Strong; Christopher I Amos
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

8.  Follow-up study of twenty-four families with Li-Fraumeni syndrome.

Authors:  J E Garber; A M Goldstein; A F Kantor; M G Dreyfus; J F Fraumeni; F P Li
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

9.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Authors:  Patrick Dumont; J I-Ju Leu; Anthony C Della Pietra; Donna L George; Maureen Murphy
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

10.  TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.

Authors:  V Marcel; E I Palmero; P Falagan-Lotsch; G Martel-Planche; P Ashton-Prolla; M Olivier; R R Brentani; P Hainaut; M I Achatz
Journal:  J Med Genet       Date:  2009-06-18       Impact factor: 6.318

View more
  6 in total

1.  Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.

Authors:  Phuong L Mai; Payal P Khincha; Jennifer T Loud; Rosamma M DeCastro; Renée C Bremer; June A Peters; Chia-Ying Liu; David A Bluemke; Ashkan A Malayeri; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

3.  Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition.

Authors:  Phuong L Mai; Sharon R Sand; Neiladri Saha; Mauricio Oberti; Tom Dolafi; Lisa DiGianni; Elizabeth J Root; Xianhua Kong; Renee C Bremer; Karina M Santiago; Jasmina Bojadzieva; Derek Barley; Ana Novokmet; Karen A Ketchum; Ngoc Nguyen; Shine Jacob; Kim E Nichols; Christian P Kratz; Joshua D Schiffman; D Gareth Evans; Maria Isabel Achatz; Louise C Strong; Judy E Garber; Sweta A Ladwa; David Malkin; Jeffrey N Weitzel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-10       Impact factor: 4.254

4.  Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.

Authors:  Assunta De Rienzo; Michael A Archer; Beow Y Yeap; Nhien Dao; Daniele Sciaranghella; Antonios C Sideris; Yifan Zheng; Alexander G Holman; Yaoyu E Wang; Paola S Dal Cin; Jonathan A Fletcher; Renee Rubio; Larry Croft; John Quackenbush; Peter E Sugarbaker; Kiara J Munir; Jesse R Battilana; Corinne E Gustafson; Lucian R Chirieac; Soo Meng Ching; James Wong; Liang Chung Tay; Stephen Rudd; Robert Hercus; David J Sugarbaker; William G Richards; Raphael Bueno
Journal:  Cancer Res       Date:  2015-11-10       Impact factor: 12.701

5.  Analysis of mutations in cutaneous squamous cell carcinoma reveals novel genes and mutations associated with patient-specific characteristics and metastasis: a systematic review.

Authors:  Marissa B Lobl; Dillon Clarey; Cynthia Schmidt; Christopher Wichman; Ashley Wysong
Journal:  Arch Dermatol Res       Date:  2021-03-18       Impact factor: 3.033

Review 6.  Sex differences in the response to oxidative and proteolytic stress.

Authors:  John Tower; Laura C D Pomatto; Kelvin J A Davies
Journal:  Redox Biol       Date:  2020-03-09       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.